SCHEMBL13288895

SCHEMBL13288895

Bc1cnn2c(NCCNC(=O)c3ccc(NC(C)=O)cc3)cc(-c3ccccc3Cl)nc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GSK3B P49841 4/20 0.43
▸ CDK2 P24941 3/20 0.43
▸ ALDH1A1 P00352 5/20 0.40
▸ MEN1 O00255 4/20 0.40
▸ KMT2A Q03164 4/20 0.40
▸ SMN1; SMN2 Q16637 3/20 0.40
▸ RAB9A P51151 3/20 0.40
▸ KDM4E B2RXH2 2/20 0.40
▸ NPC1 O15118 2/20 0.40
▸ LMNA P02545 2/20 0.40
▸ MAPT P10636 2/20 0.40
▸ HPGD P15428 2/20 0.40
▸ CLK1 P49759 1/20 0.40
▸ HTT P42858 3/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ NFKB1 P19838 1/20 0.39
▸ KCNH2 Q12809 1/20 0.39
▸ CYP3A4 P08684 2/20 0.38
▸ POLB P06746 2/20 0.38
▸ THRB P10828 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14561755 0.91 GSK3B (0.56) GSK3BCDK2ALDH1A1MEN1KMT2A
SCHEMBL13288754 0.89 CDK2 (0.45) GSK3BCDK2MEN1KMT2ASMN1; SMN2
SCHEMBL14545970 0.87 GSK3B (0.45) GSK3BCDK2CYP1A2CYP2D6CYP2C19
SCHEMBL13288943 0.87 BRD4 (0.44) GSK3BCDK2ALDH1A1MEN1KMT2A
SCHEMBL14545832 0.87 CDK2 (0.48) GSK3BCDK2ALDH1A1SMN1; SMN2RAB9A
SCHEMBL13120086 0.86 GSK3B (0.55) GSK3BCDK2ALDH1A1MEN1KMT2A
SCHEMBL13120159 0.86 GSK3B (0.55) GSK3BCDK2ALDH1A1MEN1KMT2A
SCHEMBL13289235 0.85 CDK2 (0.45) GSK3BCDK2ALDH1A1KMT2AHPGD
SCHEMBL13288899 0.85 GSK3B (0.43) GSK3BCDK2ALDH1A1MEN1KMT2A
SCHEMBL14545261 0.84 CDK2 (0.53) GSK3BCDK2MEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2194058-A1 Pyrazolopyrimidines suitable for the treatment of cancer diseases SCHERING CORPORATION (US) 2010-06-09 — — EP disclosed
Send feedback